Home >> Tag Archives: AstraZeneca—

Tag Archives: AstraZeneca—

Resectability in stage III NSCLC:
Case-based considerations for clinical decision making

Webinar presenters Michael Walker, MD, System Chief, Thoracic Surgery, Medical Director, Cancer Program, Main Line Health, and Tracey Evans, MD, Director, Thoracic Oncology Research, Co-Director, Thoracic Oncology Program, Associate Program Director, Hematology/Medical Oncology Fellowship Program, Lankenau Cancer Center, discuss AJCC staging guidelines for lung cancer, specifically Stage III disease. This on-demand webinar originally broadcast on November 14, 2018.

Read More »

Developing perspectives on BRCA testing: new horizons for breast cancer

Webinar presenters Tabetha Sundin, PhD, HCLD(ABB), MB(ASCP)CM and Leigha Senter-Jamieson, MS, discuss the rationale for BRCA mutation testing in breast cancer, key highlights of the BRCA testing and interpretation process, and reconsidering multi-disciplinary team roles and responsibilities to streamline the testing experience. This on-demand webinar was originally broadcast on March 29, 2018.

Read More »

FDA OKs Imfinzi for unresectable stage III NSCLC

March 13, 2018—AstraZeneca and MedImmune, its biologics research and development arm, announced the FDA has approved Imfinzi (durvalumab) for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. “This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the ...

Read More »